Amgen stock edges toward analyst targets on solid fundamentals

Published on 09/21/2026 at 14:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Amgen stock recently closed at USD 385.65 on Nasdaq on September 18, 2026, leaving it close to the average analyst target near USD 387.69. Recent quarters have seen strong earnings momentum, underpinning the valuation and dividend profile for long-term investors.

Fotorealistische moderne Biotech-Produktionsanlage mit Glasfassade, Bioreaktoren und Palmen unter blauem Himmel — Amgen Inc. (ISIN US0311621009) zeigt fotorealistisch eine moderne Biotech-Anlage mit Bioreaktoren in Kalifornien, Illustration mit AI erstellt.

Amgen stock (ISIN US0311621009) most recently closed at USD 385.65 on Nasdaq on September 18, 2026, a level that sits close to the average analyst target price of about USD 387.69 per data compiled in mid September 2026. According to consensus figures summarized by MarketScreener, that average target leaves limited upside from the latest close, while still signaling confidence in Amgen's earnings trajectory as of September 19, 2026.

Earnings momentum supports Amgen stock

In recent quarters, Amgen has reported earnings that financial portals characterize as beats versus market expectations, which helps explain why Amgen stock is trading close to its analyst target range as of mid September 2026. One such portal notes that Amgen shares were up around 1.55% in the latest session on the back of bullish technical signals and strong earnings beats, with the stock changing hands near USD 385.65 as of September 19, 2026, underscoring the market's positive reaction to the company’s results and outlook, as highlighted by Pluang.

Consensus data compiled around September 19, 2026 show Amgen's last close at USD 385.65, compared with an average analyst target of approximately USD 387.69 and a high target of USD 457.00 and a low target of USD 225.00 in the same overview. According to the figures presented by MarketScreener, the current price of around USD 385.65 stands only about USD 2.04, or roughly 0.5%, below the average target, but still nearly USD 71.35, or about 18.5%, below the highest analyst price objective of USD 457.00 as of that date.

Dividend growth and valuation context

Besides earnings momentum, Amgen stock also benefits from a strong record of dividend growth, which matters for income-oriented investors assessing large-cap healthcare names. A recent overview of healthcare dividend payers lists Amgen with a dividend growth grade of A- alongside peers such as AbbVie, indicating that the company has consistently increased its payout over time and that its dividend track record compares favorably within the sector, according to Seeking Alpha on September 21, 2026.

For valuation, the same consensus snapshot indicates Amgen shares have gained about 17.82% since the start of 2026, with a five-day change of roughly +1.56% as of September 19, 2026. In that context, the last close of USD 385.65 versus the average target of USD 387.69 suggests that the market has already priced in much of the expected earnings and dividend story, yet leaves room for additional upside if the company continues to deliver above-consensus results and maintains its dividend growth trajectory, based on data compiled by MarketScreener.

Current price, range and investor view

Per recent real-time quote information, Amgen stock traded between an intraday low of USD 376.86 and a high of USD 386.50 on Nasdaq on September 21, 2026, with the shares quoted at around USD 385.25 at one point, corresponding to roughly 2.2% above the day's low and 0.3% below the day's high. A stock overview for the ticker AMGN also shows a market capitalization of about USD 208.45 billion at that price level as of September 21, 2026, illustrating Amgen's position as one of the larger constituents in the global biotechnology space, according to data presented on a major trading platform on that date.